Table 4.
GSEA enrichment analysis results.
| ID | setSize | NES | FDR |
|---|---|---|---|
| KEGG_CELL_CYCLE | 124 | 1.89 | 6.75E-02 |
| KEGG_ECM_RECEPTOR_INTERACTION | 84 | 1.70 | 6.75E-02 |
| KEGG_DNA_REPLICATION | 36 | 1.60 | 1.63E-01 |
| KEGG_BLADDER_CANCER | 41 | 1.60 | 1.49E-01 |
| KEGG_TASTE_TRANSDUCTION | 51 | 1.57 | 1.34E-01 |
| KEGG_GLIOMA | 65 | 1.42 | 2.51E-01 |
| KEGG_AXON_GUIDANCE | 128 | 1.40 | 2.06E-01 |
| KEGG_CALCIUM_SIGNALING_PATHWAY | 177 | 1.36 | 1.78E-01 |
| KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION | 271 | 1.34 | 1.45E-01 |
| KEGG_FOCAL_ADHESION | 197 | 1.32 | 2.44E-01 |
| KEGG_PATHWAYS_IN_CANCER | 322 | 1.31 | 1.60E-01 |
| KEGG_CELL_ADHESION_MOLECULES_CAMS | 128 | -1.32 | 2.18E-01 |
| KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION | 261 | -1.44 | 1.51E-01 |
| KEGG_JAK_STAT_SIGNALING_PATHWAY | 155 | -1.55 | 1.09E-01 |
| KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY | 131 | -1.55 | 1.47E-01 |
| KEGG_DRUG_METABOLISM_OTHER_ENZYMES | 51 | -1.57 | 1.43E-01 |
| KEGG_BETA_ALANINE_METABOLISM | 22 | -1.58 | 2.25E-01 |
| KEGG_LEISHMANIA_INFECTION | 69 | -1.62 | 1.21E-01 |
| KEGG_VIRAL_MYOCARDITIS | 68 | -1.69 | 8.83E-02 |
| KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY | 107 | -1.77 | 9.18E-02 |
| KEGG_CYTOSOLIC_DNA_SENSING_PATHWAY | 53 | -1.84 | 8.78E-02 |
| KEGG_HEMATOPOIETIC_CELL_LINEAGE | 85 | -1.92 | 9.18E-02 |
| KEGG_AUTOIMMUNE_THYROID_DISEASE | 50 | -1.93 | 8.83E-02 |
| KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PRODUCTION | 46 | -2.12 | 8.83E-02 |
| KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION | 80 | -2.18 | 8.87E-02 |
| KEGG_ASTHMA | 28 | -2.20 | 8.20E-02 |
| KEGG_TYPE_I_DIABETES_MELLITUS | 41 | -2.25 | 8.44E-02 |
| KEGG_PRIMARY_IMMUNODEFICIENCY | 35 | -2.31 | 8.44E-02 |
| KEGG_GRAFT_VERSUS_HOST_DISEASE | 37 | -2.65 | 8.44E-02 |
| KEGG_ALLOGRAFT_REJECTION | 35 | -2.65 | 8.44E-02 |